Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | SMO | Q99835 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | CRHBP | P24387 | 2/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7249246 | 0.89 | RXFP1 (0.50) | RXFP1POLBMAPTNPSR1PKM | |
| SCHEMBL7243166 | 0.89 | RXFP1 (0.48) | RXFP1POLBMAPTNPSR1PKM | |
| SCHEMBL7249285 | 0.88 | RXFP1 (0.58) | RXFP1POLBMAPTNPSR1PKM | |
| SCHEMBL7242713 | 0.87 | RXFP1 (0.46) | RXFP1POLBMAPTNPSR1PKM | |
| SCHEMBL7242624 | 0.84 | MAPT (0.65) | RXFP1POLBMAPTNPSR1PKM | |
| SCHEMBL7241756 | 0.83 | MAPT (0.51) | RXFP1POLBMAPTNPSR1PKM | |
| SCHEMBL7242880 | 0.83 | MAPT (0.48) | RXFP1POLBMAPTNPSR1PKM | |
| SCHEMBL7244034 | 0.82 | POLB (0.55) | RXFP1POLBMAPTNPSR1PKM | |
| SCHEMBL7241998 | 0.82 | KMT2A (0.53) | RXFP1POLBMAPTNPSR1TP53 | |
| SCHEMBL7245777 | 0.82 | MAPT (0.52) | RXFP1POLBMAPTNPSR1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030045532-A1 | Triazolo-pyrimidine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2003-03-06 | — | — | US | claimed |
| US-20030045532-A1 | Triazolo-pyrimidine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045532-A1 | Triazolo-pyrimidine derivatives as ligands for gaba receptors | GABRA3, GABRA2, GABRA4 | RXFP1 1388/4885POLB 3552/4885MAPT 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.